(PDF) P3.01-002 Concurrent EGFR T790M Secondary Mutation

P3.01-002 Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient With EGFR TKI Drug Resistance

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2017.09.1444

Full Text

Open PDF

Abstract

Available in full text

Date

November 1, 2017

Authors

Publisher

Elsevier BV

Related search

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Molecular Cancer Therapeutics

Cancer Research

Oncology

2016

English

Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients

English

Combined Therapy With EGFR TKI and Gambogic Acid for Overcoming Resistance in EGFR‑T790M Mutant Lung Cancer

English

P063 STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma

Journal of Thoracic Oncology

English

P3.01-24 the Importance to Switch From EGFR-TKI to Cytotoxic Chemotherapy for EGFR Mutation-Positive Adenocarcinoma

Journal of Thoracic Oncology

English

Squamous Cell Carcinoma “Transformation” Concurrent With Secondary T790M Mutation in Resistant EGFR -Mutated Adenocarcinomas

Journal of Thoracic Oncology

English

Squamous Cell Transformation and EGFR T790M Mutation as Acquired Resistance Mechanisms in a Patient With Lung Adenocarcinoma Treated With a Tyrosine Kinase Inhibitor: A Case Report

English

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

English

Case Report: Temporal Heterogeneity of Resistance Mechanisms to EGFR-TKI Identified in a Lung Adenocarcinoma Patient With Sarcomatoid Transformation

English

Amanote Research

P3.01-002 Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient With EGFR TKI Drug Resistance

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2017.09.1444

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients

Combined Therapy With EGFR TKI and Gambogic Acid for Overcoming Resistance in EGFR‑T790M Mutant Lung Cancer

P063 STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma

P3.01-24 the Importance to Switch From EGFR-TKI to Cytotoxic Chemotherapy for EGFR Mutation-Positive Adenocarcinoma

Squamous Cell Carcinoma “Transformation” Concurrent With Secondary T790M Mutation in Resistant EGFR -Mutated Adenocarcinomas

Squamous Cell Transformation and EGFR T790M Mutation as Acquired Resistance Mechanisms in a Patient With Lung Adenocarcinoma Treated With a Tyrosine Kinase Inhibitor: A Case Report

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

Case Report: Temporal Heterogeneity of Resistance Mechanisms to EGFR-TKI Identified in a Lung Adenocarcinoma Patient With Sarcomatoid Transformation